EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure

Yusuke Kashiwagi, Tomohisa Nagoshi, Haruka Kimura, Yoshiro Tanaka, Yuhei Oi, Yasunori Inoue, Kazuo Ogawa, Makoto Kawai, Michihiro Yoshimura

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Yusuke Kashiwagi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Heart Failure, Insulin Resistance, Insulins, Ventricular Dysfunction, Left. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although the haemodynamic effects of angiotensin receptor-neprilysin inhibitor (ARNI) on patients with heart failure have been demonstrated, the effect on glucose metabolism has not been fully elucidated. We retrospectively investigated the effect of ARNI on abnormal glucose metabolism in patients with stable chronic heart failure using an additional structural equation model (SEM) analysis.

Methods

We analysed 34 patients who regularly visited to the outpatient department of our institute with heart failure from October 2021 and July 2022 and who were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Seventeen patients switched from ACE inhibitors or ARBs to an ARNI (ARNI group), and the other 17 patients continued treatment with ACE inhibitors or ARBs (control group).

Results

At baseline, although the ARNI group included fewer patients with heart failure with preserved ejection fraction in comparison with the control group (P = 0.004), patients with heart failure with mildly reduced ejection fraction, and heart failure with reduced ejection fraction were mostly biased towards the ARNI group (although not statistically significant). The baseline insulin resistance in the ARNI group was already significantly higher in comparison with the control group [fasting blood insulin, 9.7 (7.4, 11.6) vs. 7.8 (5.2, 9.2) μU/mL, P = 0.033; homoeostasis model assessment of insulin resistance (HOMA-IR), 3.10 (1.95, 4.19) vs. 2.02 (1.56, 2.42), P = 0.014]. Three months later, the fasting blood insulin and the HOMA-IR levels were both found to have decreased in comparison with the baseline values [baseline to 3 months: insulin, 9.7 (7.4, 11.6) to 7.3 (4.6, 9.4) μU/mL, P < 0.001; HOMA-IR, 3.10 (1.95, 4.19) to 1.96 (1.23, 3.09), P < 0.001]. An additional SEM analysis demonstrated that the initiation of ARNI had caused a reduction in the fasting blood insulin and the HOMA-IR levels at 3 months independently of the baseline fasting blood insulin and HOMA-IR levels, respectively. Similarly, the initiation of ARNI resulted in a significant reduction in serum uric acid levels (6.28 ± 0.35 to 5.80 ± 0.30 mg/dL, P = 0.008).

Conclusions

In conclusion, even in a short period of only 3 months, the administration of ARNI improved insulin resistance and consequently reduced the serum uric acid levels in patients with stable chronic heart failure. Although the ARNI group already had high insulin resistance at baseline, an additional SEM analysis revealed that the decreased insulin resistance was truly due to the effect of ARNI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureInsulin ResistanceInsulinsVentricular Dysfunction, LeftHumansAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsGlucoseNeprilysinRetrospective StudiesStroke VolumeTreatment OutcomeUric Acid

Stichwörter der Autor:innen

Angiotensin receptor-neprilysin inhibitorHeart failureInsulin resistanceStructural equation model analysisUric acid

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsGlucoseInsulinsNeprilysinUric Acid

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Zitieren

APA

Kashiwagi, Y., Nagoshi, T., Kimura, H., Tanaka, Y., Oi, Y., Inoue, Y., Ogawa, K., Kawai, M., & Yoshimura, M. (2023). Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.14352

Vancouver

Kashiwagi Y, Nagoshi T, Kimura H, Tanaka Y, Oi Y, Inoue Y, et al. Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure. ESC Heart Failure. 2023. doi:10.1002/ehf2.14352

BibTeX
@article{Kashiwagi2023,
  author = {Kashiwagi, Yusuke and Nagoshi, Tomohisa and Kimura, Haruka and Tanaka, Yoshiro and Oi, Yuhei and Inoue, Yasunori and Ogawa, Kazuo and Kawai, Makoto and Yoshimura, Michihiro},
  title = {Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14352}
}
Kostenlos starten →